{"name":"Anika Therapeutics","slug":"anika-therapeutics","ticker":"ANIK","exchange":"NASDAQ","domain":"anika.com","description":"Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a hi","hq":"Bedford, MA","founded":0,"employees":"235","ceo":"","sector":"Regenerative Medicine / Orthopedics","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":15.4,"stockChange":0.6,"stockChangePercent":4.05,"marketCap":"$205M","metrics":{"revenue":116263000,"revenueGrowth":13.2,"grossMargin":58.6,"rdSpend":0,"netIncome":-11077000,"cash":41020000,"dividendYield":0,"peRatio":33.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cingal","genericName":"Cingal","slug":"cingal","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Cingal","genericName":"Cingal","slug":"cingal","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":112819000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":112819000},{"period":"2024-12-31","value":119907000},{"period":"2023-12-31","value":120792000},{"period":"2022-12-31","value":113827000}],"grossProfit":63807000,"grossProfitHistory":[{"period":"2025-12-31","value":63807000},{"period":"2024-12-31","value":75998000},{"period":"2023-12-31","value":82532000},{"period":"2022-12-31","value":73220000}],"rdSpend":25770000,"rdSpendHistory":[{"period":"2025-12-31","value":25770000},{"period":"2024-12-31","value":25544000},{"period":"2023-12-31","value":21763000},{"period":"2022-12-31","value":18321000}],"sgaSpend":49088000,"operatingIncome":-11051000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-11051000},{"period":"2024-12-31","value":-5101000},{"period":"2023-12-31","value":844000},{"period":"2022-12-31","value":3670000}],"netIncome":-10880000,"netIncomeHistory":[{"period":"2025-12-31","value":-10880000},{"period":"2024-12-31","value":-56385000},{"period":"2023-12-31","value":-82667000},{"period":"2022-12-31","value":-14859000}],"eps":-0.76,"epsHistory":[{"period":"2025-12-31","value":-0.76},{"period":"2024-12-31","value":-3.83},{"period":"2023-12-31","value":-5.64},{"period":"2022-12-31","value":-1.02}],"cash":57481000,"cashHistory":[{"period":"2025-12-31","value":57481000},{"period":"2024-12-31","value":55629000},{"period":"2023-12-31","value":68740000},{"period":"2022-12-31","value":86327000}],"totalAssets":190270000,"totalLiabilities":46805000,"totalDebt":26248000,"equity":143465000,"operatingCashflow":11188000,"operatingCashflowHistory":[{"period":"2025-12-31","value":11188000},{"period":"2024-12-31","value":5403000},{"period":"2023-12-31","value":-1788000},{"period":"2022-12-31","value":4409000}],"capex":-6826000,"capexHistory":[{"period":"2025-12-31","value":-6826000},{"period":"2024-12-31","value":-8334000},{"period":"2023-12-31","value":-5427000},{"period":"2022-12-31","value":-7486000}],"freeCashflow":4362000,"dividendsPaid":null,"buybacks":-9485000,"employees":235,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":17772000,"ebit":-5488000,"ebitda":-4081000,"period":"2026-03-31","revenue":29612000,"epsBasic":-0.37,"netIncome":-5056000,"rdExpense":6713000,"epsDiluted":-0.37,"grossProfit":18997000,"operatingIncome":-5488000},{"sga":12081000,"ebit":646000,"ebitda":1964000,"period":"2025-12-31","revenue":30615000,"epsBasic":0.02,"netIncome":292000,"rdExpense":6452000,"epsDiluted":0.02,"grossProfit":19179000,"operatingIncome":646000},{"sga":11871000,"ebit":-3233000,"ebitda":-1830000,"period":"2025-09-30","revenue":27817000,"epsBasic":-0.16,"netIncome":-2329000,"rdExpense":6946000,"epsDiluted":-0.16,"grossProfit":15584000,"operatingIncome":-3233000},{"sga":12230000,"ebit":-4180000,"ebitda":-2764000,"period":"2025-06-30","revenue":28219000,"epsBasic":-0.28,"netIncome":-3970000,"rdExpense":6313000,"epsDiluted":-0.28,"grossProfit":14363000,"operatingIncome":-4180000},{"sga":12906000,"ebit":-4284000,"ebitda":-2692000,"period":"2025-03-31","revenue":26168000,"epsBasic":-0.34,"netIncome":-4873000,"rdExpense":6059000,"epsDiluted":-0.34,"grossProfit":14681000,"operatingIncome":-4284000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":15.4,"previousClose":14.8,"fiftyTwoWeekHigh":16.24,"fiftyTwoWeekLow":7.87,"fiftyTwoWeekRange":"7.87 - 16.24","fiftyDayAverage":14.7,"twoHundredDayAverage":10.84,"beta":0.16,"enterpriseValue":181639232,"forwardPE":33.5,"priceToBook":1.54,"priceToSales":1.76,"enterpriseToRevenue":1.56,"enterpriseToEbitda":-26.48,"pegRatio":3.6,"ebitda":-6860000,"ebitdaMargin":-5.9,"freeCashflow":6358625,"operatingCashflow":6472000,"totalDebt":25736000,"debtToEquity":19.2,"currentRatio":4.46,"returnOnAssets":-4.1,"returnOnEquity":-7.8,"analystRating":"1.5 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":2,"targetMeanPrice":17.5,"targetHighPrice":18,"targetLowPrice":17,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":6,"institutionHeldPercent":93.5,"sharesOutstanding":13305624,"floatShares":11295543,"sharesShort":552247,"shortRatio":4.23,"shortPercentOfFloat":4.2,"epsTrailing":-0.79,"epsForward":0.46,"revenuePerShare":8.22,"bookValue":10.03,"officers":[{"age":61,"name":"Dr. Cheryl Renee Blanchard Ph.D.","title":"Executive Chair"},{"age":39,"name":"Mr. Stephen D. Griffin","title":"President, Principal Financial Officer, CEO & Director"},{"age":59,"name":"Mr. Ian W. McLeod","title":"Senior VP, Chief Accounting Officer & Treasurer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.anika.com","phone":"781 457 9000"}}